@article{fd4e04cb34924461a205da0a3a7b8200,
title = "Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis",
abstract = "In ankylosing spondylitis (AS), structural damage that occurs as a result of syndesmophyte formation and ankylosis of the vertebral column is irreversible. Structural damage is currently assessed by conventional radiography and scoring systems that reliably assess radiographic structural damage are needed to capture the differential effects of drugs on structural damage progression. The validity of the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) as a primary outcome measure in evaluating the effect of AS treatments on radiographic progression rates was assessed in this review. The mSASSS has not been used, to date, as a primary outcome measure in a prospective randomized controlled clinical trial of biologic therapy in AS. This review of the medical literature confirmed that the mSASSS is the most validated and widely used method for assessing radiographic progression in AS, correlating with worsening measures of disease signs and symptoms, spinal mobility and physical function, with a 2-year interval being required to ensure sufficient sensitivity to change.",
keywords = "ankylosing spondylitis, imaging, mSASSS, radiograph, radiography, scoring, spondyloarthritis",
author = "{Van Der Heijde}, D{\'e}sir{\'e}e and J{\"u}rgen Braun and Atul Deodhar and Xenofon Baraliakos and Robert Landew{\'e} and Richards, {Hanno B.} and Brian Porter and Aimee Readie",
note = "Funding Information: The authors thank Aisling O{\textquoteright}Keeffe, PhD of Novartis Ireland Ltd, Dublin, Ireland for providing medical writing support, which was funded by Novartis, in accordance with Good Publication Practice (GPP3) guidelines (http:// www.ismpp.org/gpp3). D.vd.H., J.B., A.D., X.B., R.L., H.B.R., B.P. and A.R. participated in the development of the manuscript, including advising on which papers should be reviewed and cited. All authors agreed on the content, reviewed drafts and approved the final version. Funding Information: Disclosure statement: D.vd.H. has been a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb (BMS), Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB and is an employee of Imaging Rheumatology BV. J.B. has received grant/research support from Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, has been a consultant for Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB and received speakers fees from AbbVie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB. A.D. has received grant/research support from Eli Lilly, GSK, Janssen, Novartis, Pfizer, Sun Pharma, UCB and has been a consultant for AbbVie, Eli Lilly, GlaxoSmithKline (GSK), Janssen, Novartis, Pfizer, UCB. X.B. has received grant/research support from AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, Werfen, been a consultant for AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, Werfen, received speakers fees from AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, Werfen. R.L. has received grant/research support from Abbvie (Abbott), Amgen, Centocor, Novartis, Pfizer, Roche, Schering, UCB, been a consultant for Abbvie (Abbott), Ablynx, Amgen, Astra-Zeneca, Bristol Myers Squibb, Celgene, Eli-Lilly, Janssen, Gilead, Galapagos, Glaxo-Smith-Kline, Novartis, Novo Nordisk, Merck, Pfizer, Roche, Schering, TiGenix, UCB, is an employee of Rheumatology Consultancy BV and received speakers fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Merck, Pfizer, Roche, Schering, UCB. H.B.R. is an employee of Novartis Pharma AG and a shareholder of Novartis. B.P. and A.R. are employees of Novartis Pharmaceuticals Corporation and shareholders of Novartis.",
year = "2019",
month = mar,
day = "1",
doi = "10.1093/rheumatology/key128",
language = "English (US)",
volume = "58",
pages = "388--400",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "3",
}